"The U.S. Food and Drug Administration today approved Orbactiv (oritavancin), a new antibacterial drug to treat adults with skin infections.
Orbactiv is approved to treat patients with acute bacterial skin and skin structure infections (ABSS"...
Clinical Trials Experience
Because clinical trials are conducted under controlled but widely varying conditions, adverse reaction rates observed in clinical trials of Varithena™ cannot be directly compared to rates in the clinical trials of other drugs or procedures and may not reflect the rates observed in practice.
A total of 1333 patients in 12 clinical trials were evaluated for safety when treated with Varithena™ at dose concentrations of 0.125%, 0.5%, 1.0%, or 2.0%, including 437 patients treated with Varithena™ in placebo-controlled clinical trials.
Adverse reactions occurring in 3% more patients receiving Varithena™ 1% than receiving placebo are shown in Table 1.
Table 1: Treatment-emergent adverse reactions (3% more on Varithena™ 1% than on placebo) through Week 8 (n=588)
|Adverse Reaction|| Placebo
| Varithena™ 1.0%
| Pooleda Varithena™ |
|Pain in extremity||14 (9.3)||25 (16.8)||65 (14.9)|
|Infusion site thrombosisb||0||24 (16.1)||46 (10.5)|
|Contusion/injection site hematoma||9 (6.0)||23 (15.4)||38 (8.7)|
|Limb discomfort||5 (3.3)||18 (12.1)||32 (7.3)|
|Tenderness/injection site pain||5 (3.3)||16 (10.7)||30 (6.9)|
|Venous thrombosis limbc||0||12 (8.1)||24 (5.5)|
|Thrombophlebitis superficial||2 (1.3)||8 (5.4)||40 (9.2)|
|Deep vein thrombosis||0||7 (4.7)||10 (2.3)|
| a Includes Varithena™ 0.125%, 0.5%, 1.0%, and 2.0% from the placebo-controlled trials. |
b Retained coagulum.
c Common femoral vein thrombus extension (non-occlusive thrombi starting in the superficial vein and extending into the common femoral vein).
In Varithena™-treated patients, 80% of pain events in the treated extremity resolved within 1 week.
In the 1333 patients treated with Varithena™, the following venous thrombus adverse events occurred: common femoral vein thrombus extension (2.9%), proximal deep vein thrombosis (DVT) (1.7%), distal DVT (1.1%), isolated gastrocnemius, and soleal vein thrombosis (1.4%).
Proximal symptomatic venous thrombi occurred in <1% of patients treated with Varithena™. Approximately half (49%) of patients with thrombi received treatment with anticoagulants.
Since Varithena™ induces thrombosis in the treated superficial veins, D-dimer is commonly elevated post-treatment and is not useful diagnostically to assess patients for venous thrombus following treatment with Varithena™.
Neurologic adverse events (cerebrovascular accident, migraines) have been reported in patients following administration of physician compounded foam sclerosants. None of the 1333 patients in the Varithena™ trials experienced clinically important neurological or visual adverse events suggestive of cerebral gas embolism. The incidence of neurologic and visual adverse events within 1 day of treatment in the placebo-controlled studies was 2.7% in the pooled Varithena™ group and 4.0% in the placebo groups.
Skin discoloration adverse events were reported in 1.1% of the pooled Varithena™ group and 0.7% of the placebo group in the placebo-controlled studies.
Read the Varithena (polidocanol injectable foam) Side Effects Center for a complete guide to possible side effects
No specific drug interaction studies have been performed. There are no known drug interactions with Varithena™.This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 12/4/2015
Additional Varithena Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.